All Topics
All Topics
Technology
Technology
Design
Design
Programming
Programming
Science
Science
News
News
Gaming
Gaming
Entertainment
Entertainment
Business
Business
Finance
Finance
Sports
Sports
Health
Health
Food
Food
Travel
Travel
Art
Art
Music
Music
Books
Books
Education
Education
Politics
Politics
Personal
Personal
No algorithm. No AI slop. No ads. Just RSS. Pro-human. Indie writers. Real journalism. Open web. Chronological. Hand toasted.

GSK in talks to acquire Nuvalent for over $9 billion in largest deal in more than a decade

By

Anniek Bao

18h ago· 3 min readenNews

Summary

GSK is in talks to acquire biotech firm Nuvalent for more than $9 billion, which would be its largest acquisition in over a decade and the second largest in its history, trailing only its 2014 asset swap with Novartis. The deal marks a shift from GSK's recent focus on smaller transactions in the £2-4 billion range, as CEO Luke Miels pursues larger M&A. The acquisition comes amid a biotech dealmaking frenzy driven by patent cliffs, buoyant public markets, and drugmakers' need to strengthen their pipelines.

Key quotes

· 3 pulled
The deal would be the second largest acquisition in GSK's history, the FT reported, trailing its 2014 asset swap with Novartis in which it assumed control of the Swiss drugmaker's vaccines division in a transaction valued at $20 billion.
It would also mark a notable departure from the company's focus on smaller transactions in recent years.
GSK chief executive Luke Miels, who took over the job from longtime boss Emma Walmsley at the start of the year, told investors in February that he would focus on transactions in the £2 billion to £4 billion range
Snippet from the RSS feed
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.

You might also wanna read